Showing results (101-110 of 408) with videos related to

Sort By:
Pageof 41
Blood|September 29, 2012
Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab/R-CHOPMamta Gupta, Matthew J Maurer, Linda E Wellik, et al.
Leukemia & Lymphoma|February 14, 2015
Early treatment of high risk chronic lymphocytic leukemia with alemtuzumab, rituximab and poly-(1-6)-beta-glucotriosyl-(1-3)- beta-glucopyranose beta-glucan is well tolerated and achieves high complete remission ratesClive S Zent, Timothy G Call, Deborah A Bowen, et al.
British Journal of Haematology|October 9, 2003
Plasma levels of tumour necrosis factor alpha and interleukin-6 predict progression-free survival following thalidomide therapy in patients with previously untreated multiple myelomaMichael A Thompson, Thomas E Witzig, Shaji Kumar, et al.
Gastroenterology|January 10, 2002
Epstein-Barr virus-positive lymphoma in patients with inflammatory bowel disease treated with azathioprine or 6-mercaptopurineGerald A Dayharsh, Edward V Loftus, William J Sandborn, et al.
British Journal of Haematology|May 15, 2015
A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402Thomas E Witzig, Fangxin Hong, Ivana N Micallef, et al.
Cancer|April 16, 2011
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotypeFrancisco J Hernandez-Ilizaliturri, George Deeb, Pier L Zinzani, et al.
Translational Research : the Journal of Laboratory and Clinical Medicine|March 27, 2007
Serum-free light chain-a new biomarker for patients with B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemiaWilliam Martin, Roshini Abraham, Tait Shanafelt, et al.
Mayo Clinic Proceedings|June 7, 2007
Treatment of benign orbital pseudolymphomas with the monoclonal anti-CD20 antibody rituximabThomas E Witzig, David J Inwards, Thomas M Habermann, et al.
Blood|December 31, 2002
Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disordersAnimesh Pardanani, Terra Reeder, Luis F Porrata, et al.
Cancer|March 24, 2007
Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetanThomas E Witzig, Arturo Molina, Leo I Gordon, et al.
Pageof 41